drug
bexagliflozin
Marketedupdated 4mo agoby TheracosBio LLC
Approvedcommunity read0 votes
indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 20, 2028
~1.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- May 14, 2032compositionUS 8987323
- Jul 3, 2031method-of-use (U-2214)US 105330324.8y
- Jun 13, 2031compositionUS 109819424.8y
- Jan 30, 2029compositionUS 78384992.4y
- Aug 22, 2028method-of-use (U-2214)US 81060212.0y
- Aug 22, 2028compositionUS 88026372.0y
FDA exclusivities (1)
- Jan 20, 2028NCENew Chemical Entity (5y)1.4y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that